Accessibility Menu

DataMEDS Ai(NASDAQ) MEDS

Market Cap$3.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-99%
5 YearN/A
1 Year-98%
1 Month-57%
$1.36
+4.62%
+0.06Today
After hours$1.36+$0.00 (+0.00%)
DataMEDS Ai last closing stock price
MetricPriceDate
Last closeUSD 1.362026-08-25
DataMEDS Ai stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.45%USD 1.382026-08-18
1 month-57.1%USD 3.172026-07-24
3 month-56.96%USD 3.162026-05-27
Year to date-93.19%USD 19.982025-12-31
1 year-98.34%USD 82.002025-08-25
Since inception-99.32%USD 190.502025-02-21

DataMEDS Ai Financials at a Glance

Market Cap

$3.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$8.02M

Net Income (TTM)

-$88.28M

EPS (TTM)

-$43.30

P/E Ratio

-0.03

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$1.36

Volume

42,730.961

Open

$1.32

Previous Close

$1.36

Daily Range

$1.30 - $1.36

52-Week Range

$1.26 - $97.50

Estimated Earnings Date

N/A

MEDS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About DataMEDS Ai

What’s in the Box? (Products and Services)

  • Pharmaceutical Distribution (93.7%): Supplies generic and branded drugs to pharmacies and manufacturers across the U.S.
  • Retail & Specialty Pharmacy (3.7%): Offers pharmacy services for chronic conditions, uninsured patients, and mail order in 32 states and D.C.
  • Third-Party Logistics (2.6%): Provides warehousing, inventory, and shipping for small and mid-size drug makers.
  • DelivMeds Platform: Digital hub for prescription transfers, clinical support, and patient prescription management.

Growth Spurts and Strategic Moves

  • Acquired Wood Sage in June 2024 and Wellgistics LLC in August 2024.
  • DelivMeds digital platform had not yet been placed in service as of December 31, 2025.
  • Expanded manufacturer relationships to over 60 partners and grew pharmacy network to 5,000+ locations.
  • Invested in cold chain logistics and AI-driven prescription routing in 2025.

Why Wellgistics Stands Out (Without the Hype)

Wellgistics combines wholesale, pharmacy, and technology under one roof, serving both drug makers and pharmacies. Its digital platform connects patients, pharmacies, and manufacturers for smoother prescription management. The company targets niche drugs often missed by larger distributors, giving it a unique market position.

Five Things You Need to Know

  • FY2025 net revenue was $23.3 million, up 28.8% from FY2024.
  • Q3 2025 revenue fell 80.9% year-over-year to $3 million.
  • Gross margin dropped to -27.5% in FY2025 from +9.7% in FY2024.
  • Net loss widened to $101,274,530 in FY2025 from $6,856,226 in FY2024.

Bottom Line

Wellgistics has rapidly expanded through acquisitions and technology, but faces financial and operational challenges. Its integrated approach aims to streamline drug distribution for independent pharmacies and manufacturers.

AI Generated • Apr 16, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

CEO

Gerald E. Commissiong; Prashant Patel

Website

www.wellgisticshealth.com

Headquarters

Tampa, FL 33607, US

MEDS Financials

Key Financial Metrics (TTM)

Gross Margin

-125.11%

Operating Margin

-719.27%

Net Income Margin

-1100.30%

Return on Equity

877.58%

Return on Capital

-659.05%

Return on Assets

-269.47%

Earnings Yield

-33.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.05M

Volume

42.73K

Avg. Volume

260.55K

Financials (TTM)

Gross Profit

-$10.04M

Operating Income

-$57.71M

EBITDA

-$56.41M

Operating Cash Flow

-$13.74M

Capital Expenditure

$149.68K

Free Cash Flow

-$13.59M

Cash & ST Invst.

$2.46M

Total Debt

$32.62M

DataMEDS Ai Performance Analysis

DataMEDS Ai annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 18,128,831N/A
20252025-12-31USD 23,337,86028.7%
DataMEDS Ai sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-61.3%
Q42025-12-31-44.6%
Q12026-03-31-6.6%
Q22026-06-3014.1%
DataMEDS Ai annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.01N/A
20232023-12-31USD -2.7955650.0%
20242024-12-31USD -6.60136.8%
20252025-12-31USD -49.98657.4%
DataMEDS Ai sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-318.2%
Q42025-12-3141.3%
Q12026-03-3174.1%
Q22026-06-30-103.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.78M

-77.2%

Gross Profit

-$174.39K

-134.5%

Gross Margin

-9.80%

N/A

Market Cap

$3.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$127.95K

N/A

Employees

31

N/A

Net Income

-$18.36M

-175.2%

EBITDA

-$6.99M

-49.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$2.46M

+484.9%

Total Debt

$32.62M

+31.2%

Accounts Receivable

$1.20M

-69.9%

Inventory

$1.51M

-83.3%

Long Term Debt

$12.85M

+17.7%

Short Term Debt

$19.77M

+41.7%

Return on Assets

-2.69%

N/A

Return on Invested Capital

8.67%

N/A

Free Cash Flow

-$2.69M

-21.6%

Operating Cash Flow

-$2.89M

-39.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BEATHeartBeam, Inc.
$0.50+4.10%
TELATELA Bio, Inc.
$0.70+7.03%
ALGSAligos Therapeutics, Inc.
$7.47+7.79%
KZRKezar Life Sciences, Inc.
$7.29+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$213.05+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.09+0.01%
INTCIntel
$87.48+0.00%
BITOProShares Trust - ProShares Bitcoin ETF
$10.66+0.00%

Questions About MEDS

What is the current price of DataMEDS Ai?

DataMEDS Ai is trading at $1.36 per share.

What is the 52-week range for DataMEDS Ai?

Over the past 52 weeks, DataMEDS Ai has traded between $1.26 and $97.50.

How much debt does DataMEDS Ai have?

As of the most recent reporting period, DataMEDS Ai reported total debt of $32.79M.

How much cash does DataMEDS Ai have on hand?

DataMEDS Ai reported $2.46M in cash and cash equivalents in its most recent financial results.

What is DataMEDS Ai’s dividend yield?

DataMEDS Ai does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services